Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing effectiveness monitoring of posaconazole injection and delayed-release tablets in Chinese patients with invasive aspergillosis
CTR20232647Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of posaconazole in invasive aspergillosis (IA) (2 arms), sponsored by Merck & Co. Primary endpoint: Day 42 all-cause mortality in first-line patients. Started Nov 2023; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on CTR20232647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232647.